| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.061 | 0.2 |
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.042 | 0.3 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.3 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | AZD8055 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.3 |